ReviewPharmaceuticals (Basel, Switzerland)2010
Non Steroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease.
Review in Pharmaceuticals (Basel, Switzerland), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Interventions for the management of abdominal pain in ulcerative colitis.The Cochrane database of systematic reviews · 2021Pooled it
- The epidemiology of inflammatory bowel disease: exploring the impacts of environmental factors.The Korean journal of internal medicine · 2026Review
- Therapeutic Perspective of Prodrugs of Non-Steroidal Anti-Inflammatory Drugs and Antioxidants: An Approach to Reduce Toxicity and Enhance Efficacy.Current topics in medicinal chemistry · 2026Review
- In vivo anti-inflammatory evaluation of oxadiazole derivatives bearing flurbiprofen moiety using experimental and computational approaches.Scientific reports · 2025Article
- Article
- Natural history and progression risk factors of ulcerative proctitis: a retrospective study from a single tertiary centre in Poland.Przeglad gastroenterologiczny · 2025Article
- An update on the management of axial spondyloarthritis for sports medicine professionals.BMC sports science, medicine & rehabilitation · 2024Review
- Early Life and Childhood Environmental Exposures, More Than Genetic Predisposition, Influence Age of Diagnosis in a Diverse Cohort of 2952 Patients With IBD.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024Article
- Effect ofResearch in pharmaceutical sciences · 2024Article
- Migraine is associated with the development of adult patients with inflammatory bowel disease: a nationwide, population-based study.Scientific reports · 2024Article
- Review
- Therapeutic Effect of HDAC5 Binding and Cell Penetrating Peptide for the Treatment of Inflammatory Bowel Disease.Tissue engineering and regenerative medicine · 2023Article
- Review
- Selenocoxib-3, a novel anti-inflammatory therapeutic effectively resolves colitis.Molecular and cellular biochemistry · 2023Article
- Therapeutic interventions target the NLRP3 inflammasome in ulcerative colitis: Comprehensive study.World journal of gastroenterology · 2023Review
- Medicaid Analysis of Substances of Abuse for Patients With Crohn's Disease.Gastro hep advances · 2023Article
- Recognizing Barotrauma during Colonoscopy: A Cat Scratch Colon.GE Portuguese journal of gastroenterology · 2022Article
- Enhanced Oral Bioavailability of MT-102, a New Anti-inflammatory Agent, via a Ternary Solid Dispersion Formulation.Pharmaceutics · 2022Article
- Symptoms associated with healthcare resource utilization in the setting of inflammatory bowel disease.Scientific reports · 2022Article
- Inflammatory Bowel Disease: Focus on Enteropathic Arthritis and Therapy.Rheumatology and immunology research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory Bowel Diseases (IBD) are an immune mediated chronic or relapsing disorders of the gastrointestinal (GI) tract. IBD is characterized by a chronic intestinal inflammatory process with various components contributing to the pathogenesis of the disease including environmental factors such as smoking or use of Non Steroidal Anti-Inflammatory Drugs (NSAIDS). NSAIDS are among the most commonly used medications for the treatment of various inflammatory conditions. The main factor limiting NSAIDS use is the concern for the development of gastrointestinal toxicity including mucosal injury. A possible association between the use of NSAIDS and the onset or relapse of IBD has been repeatedly suggested. This article will review the current concepts and evidence of the relationship between IBD and NSAIDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.